CSL Ltd Annual Report 2020

Specialty product sales of US$1,697 million grew 10% on a constant currency basis. The main drivers of this growth was KCENTRA ® and HAEGARDA ® . Sales of KCENTRA (4-factor prothrombin complex concentrate) in the US were strong, driven by an expansion of new accounts and expanding usage in existing accounts. HAEGARDA ® , our therapy for patients with hereditary angioedema, also grew strongly as usage increased and additional supply came on stream. Growth in specialty products was tempered by lower wound healing sales in Japan following the return to market of a competitor. Haemophilia product sales of US$1,122 million increased 8% on a constant currency basis. CSL Behring’s haemophilia portfolio continues to evolve with strong growth in the recombinant haemophilia products of 18% on a constant currency basis over the prior comparable period. This was partly offset by the continued decline in plasma-derived coagulation products which fell 3%on a constant currency basis. IDELVION ® , CSL’s Behring’s novel long-acting recombinant factor IX product for the treatment of haemophilia B, continued to grow strongly in the prophylaxis segment of the markets where we have launched the product. AFSTYLA ® , a novel recombinant factor VIII product for the treatment of haemophilia A patients, also delivered strong growth despite intense competition in this market. Plasma-derived haemophilia sales decreased due to the competitive pressures in this segment of the market. Albumin sales grew strongly in key markets with the planned exception of China, where we transitioned to our new direct distribution model. The transition has seen overall albumin sales decrease 36% to US$640 million, which is in line with guidance. Seqirus Total revenue was US$1,297 million, up 11% at constant currency basis driven by our seasonal influenza vaccines, with a significant increase in demand for FLUAD ® , Seqirus’ adjuvanted influenza vaccine for the elderly market and increased sales of FLUCELVAX ® Quadrivalent influenza vaccine. Business strategies, prospects and likely developments This operating and financial review (OFR) sets out information on CSL’s business strategies and prospects for future financial years, and refers to likely developments in CSL’s operations and the expected results of those operations in future financial years. Information in the OFR is provided to enable shareholders to make an informed assessment of the business strategies and prospects for future financial years of the CSL Group. Certain information is excluded from the OFR (which forms part of the Directors’ Report) on the basis that such information relates to impending developments or matters in the course of negotiation and disclosure would be unreasonably prejudicial to the interests of CSL. Reasons that could be considered unreasonably prejudicial to the interests of CSL include: providing information that is misleading due to the fact it is premature or preliminary in nature, relates to commercially sensitive contracts, would undermine the confidentiality between CSL and contract counterparties, or would otherwise unreasonably damage CSL. The categories of information omitted include forward looking estimates and projections prepared for internal management purposes, information which is developing and susceptible to change and information relating to commercial contracts and pricing. CSL Limited Annual Report 2020 17